ANAB remains risky despite new clinical data and partnerships; past successes haven't been replicated, and management's transparency issues raise concerns.

Announced rosnilimab, a PD-1 depleter and agonist, achieved positive results from Phase 2b rheumatoid arthritis (RA) trial and highest-ever reported CDAI LDA response over 6 monthsFull clinical and tr ...

our BDCA2 modulator Announced exclusive global license agreement with Vanda Pharmaceuticals to develop and commercialize imsidolimab, an IL-36R antagonist Year-end 2024 cash and investments of ~$420 ...

Announced rosnilimab, a PD-1 depleter and agonist, achieved positive results from Phase 2b rheumatoid arthritis (RA) trial and highest-ever ...

The company is also advancing its other candidates, including ANB033 and ANB101, and has entered into a global licensing agreement with Vanda Pharmaceuticals to develop imsidolimab, an IL-36R ...

our BDCA2 modulator Announced exclusive global license agreement with Vanda Pharmaceuticals to develop and commercialize imsidolimab, an IL-36R antagonist Year-end 2024 cash and investments of ~$ ...

SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported ...

Patients with atopic dermatitis who received daily, oral orismilast had greater reductions in Eczema Area and Severity Index scores at week 16 when compared with patients who received placebo.